Zobrazeno 1 - 10
of 578
pro vyhledávání: '"TAKASHI SETO"'
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa
Autor:
Yuka Oku, Gouji Toyokawa, Sho Wakasu, Fumihiko Kinoshita, Shinkichi Takamori, Kenji Watanabe, Naoki Haratake, Taichi Nagano, Keisuke Kosai, Kazuki Takada, Airi Fujimoto, Kodo Higashijima, Yoshimasa Shiraishi, Kentaro Tanaka, Hiroaki Takeoka, Masaki Okamoto, Takanori Yamashita, Mototsugu Shimokawa, Fumihiro Shoji, Koji Yamazaki, Tatsuro Okamoto, Takashi Seto, Hitoshi Ueda, Sadanori Takeo, Naoki Nakashima, Isamu Okamoto, Tomoyoshi Takenaka, Tomoharu Yoshizumi
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14327-14336 (2023)
Abstract Background Immunotherapy has become a standard‐of‐care for patients with non‐small‐cell lung cancer (NSCLC). Although several biomarkers, such as programmed cell death‐1, have been shown to be useful in selecting patients likely to
Externí odkaz:
https://doaj.org/article/dd568051ef63481493a1e9c73bb90058
Autor:
Minoru Fukuda, Masafumi Yamaguchi, Takuya Yamazaki, Soichiro Funaki, Hiroshi Mukae, Junya Fukuoka, Kazuki Nabeshima, Hisashi Tateyama, Kazuto Ashizawa, Noriyuki Tomiyama, Masaki Hara, Takashi Seto, Meinoshin Okumura, Kenji Sugio
Publikováno v:
Thoracic Cancer, Vol 13, Iss 17, Pp 2499-2506 (2022)
Abstract Background Combination chemotherapy is used to treat advanced thymic carcinoma; however, the effects are insufficient. Methods Previously untreated patients with unresectable locally advanced thymic carcinoma received two cycles of 80 mg/m2/
Externí odkaz:
https://doaj.org/article/d52d8cef8a754bf9bf9f39046dc2b873
Autor:
Yukio Hosomi, Takashi Seto, Makoto Nishio, Koichi Goto, Noboru Yamamoto, Isamu Okamoto, Kosei Tajima, Yusuke Kajihara, Nobuyuki Yamamoto
Publikováno v:
Thoracic Cancer, Vol 13, Iss 15, Pp 2192-2200 (2022)
Abstract Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor receptor mutation‐positive (EGFR+) non‐small cell lung
Externí odkaz:
https://doaj.org/article/bbe4a46ab03a49159a527e5397f1373b
Autor:
Yuri Taniguchi, Hiroaki Okamoto, Tsuneo Shimokawa, Tomonari Sasaki, Takashi Seto, Seiji Niho, Yuichiro Ohe, Yusuke Saigusa
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background For decades, concurrent chemo-radiotherapy with cisplatin-based regimen has been a standard therapy for locally advanced stage III non-small-cell lung cancer (NSCLC). We conducted individual-participant-data (IPD) meta-analyses to
Externí odkaz:
https://doaj.org/article/6e1fa73293354555967c1a9d5ddce6a9
Autor:
Yuki Katsuya, Shigehisa Kitano, Makiko Yamashita, Mayu Ouchi, Shigehiro Yagishita, Akinobu Hamada, Hiromi Nakamura, Fumie Hosoda, Tatsuhiro Shibata, Noriko Motoi, Takayuki Nakayama, Takashi Seto, Shigeki Umemura, Yukio Hosomi, Miyako Satouchi, Makoto Nishio, Toshiyuki Kozuki, Toyoaki Hida, Yuichiro Ohe, Hidehito Horinouchi
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in three patients and irAE (Gr2 or higher) was seen in four patients among 15 patients. Here, we report preplanned comprehensi
Externí odkaz:
https://doaj.org/article/2545d4e201224695ad24cf1e5f197dd5
Autor:
Taichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Takashi Seto, Tatsuro Okamoto
Publikováno v:
Thoracic Cancer, Vol 12, Iss 23, Pp 3286-3289 (2021)
Abstract Concurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is littl
Externí odkaz:
https://doaj.org/article/34e9b456402f4b74b9a51df3acabdd4c
Autor:
Shinkichi Takamori, Takashi Seto, Masafumi Yamaguchi, Fumihiko Kinoshita, Takatoshi Fujishita, Kensaku Ito, Ryo Toyozawa, Fumihiro Shoji, Tatsuro Okamoto
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Osimertinib is a standard therapy for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor gene (EGFR) mutations, but most patients with EGFR-mutant NSCLC develop secondary resistance to osimertinib.
Externí odkaz:
https://doaj.org/article/4ecec11b76544361abd4634eccc10400
Autor:
Yi-Long Wu, MD, Shun Lu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jianying Zhou, MD, Takashi Seto, MD, Myung-Ju Ahn, MD, PhD, Wu-Chou Su, MD, Noboru Yamamoto, MD, PhD, Dong-Wan Kim, MD, PhD, Jolanda Paolini, MSc, Tiziana Usari, BSc, Laura Iadeluca, PhD, Keith D. Wilner, PhD, Koichi Goto, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100406- (2022)
Introduction: Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data were immature. Here, we present
Externí odkaz:
https://doaj.org/article/7369e36175e44454b80a3ac673b3634f
Autor:
Shinkichi Takamori, Nobuki Furubayashi, Kenichi Taguchi, Taichi Matsubara, Takatoshi Fujishita, Kensaku Ito, Masafumi Yamaguchi, Ryo Toyozawa, Takashi Seto, Takahito Negishi, Motonobu Nakamura, Tatsuro Okamoto
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2122-2125 (2021)
Abstract Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of non‐small cell lung cancer (NSCLC). With the increasing use of ICIs, clinicians should be familiar with their immune‐related adverse events, includ
Externí odkaz:
https://doaj.org/article/2a2caac2e4584c3fb28387f6506f550b